Biosplice Announces the Submission of its New Drug Application (NDA) to the FDA for Lorecivivint (LOR) to Treat Knee Osteoarthritis

LOR is the first drug candidate with disease-modifying potential for osteoarthritis submitted for approval, demonstrating ...